RxDoctor Payments Data

Bhavesh Barad, MD

Cardiovascular Disease · Lecanto, FLNPI 1336464841

Payments from drug & device makers

$7,188in general payments, 2019–2025

Across 211 payments — averaging $34.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • AstraZeneca$494
  • Amgen$485
  • Johnson & Johnson$378
  • Novartis$307
  • Pfizer$252
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$1,02014%
  • Food & beverage$6,09485%
  • Education$360%
  • Other$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,188 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,053,197
Medicare patients
1,595
Services billed
10,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban566$612,609
EntrestoSacubitril/Valsartan390$396,384
XareltoRivaroxaban222$232,160
FarxigaDapagliflozin Propanediol205$204,429
Repatha SureclickEvolocumab88$84,501
JardianceEmpagliflozin78$77,848
Repatha SyringeEvolocumab52$40,498
Praluent PenAlirocumab26$22,606
Dabigatran EtexilateDabigatran Etexilate Mesylate65$19,447
BrilintaTicagrelor25$18,281
NexletolBempedoic Acid24$16,731
MultaqDronedarone Hcl23$16,670
Ezetimibe770$16,043
VeltassaPatiromer Calcium Sorbitex12$11,934
Rosuvastatin Calcium1,013$11,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$252$612,609566 claims
NovartisEntresto$307$396,384390 claims
Johnson & JohnsonXarelto$378$232,160222 claims
AstraZenecaFarxiga, Brilinta$494$222,710230 claims
Boehringer IngelheimJardiance$175$77,84878 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$214$22,99638 claims
Sanofi-aventis U.S. LLCMultaq$24$16,67023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Lecanto

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →